Early Identification and Treatment of Early HIV Infection in Côte d'Ivoire (PRECO-CI)
The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2013 by French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS).
Recruitment status was: Recruiting
Recruitment status was: Recruiting
Sponsor:
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Information provided by (Responsible Party):
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
ClinicalTrials.gov Identifier:
NCT01917175
First received: August 5, 2013
Last updated: NA
Last verified: August 2013
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Set-up of a biobank for patients with an estimated date of infection seroconverters: store plasma and cells samples at initial contact and during follow-up for future analysis and analysis in international collaborative cohort seroconverters.
| Condition |
|---|
|
HIV Infection |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Research Platform " Early Identification and Treatment of Early HIV Infection in Côte d'Ivoire " |
Resource links provided by NLM:
Further study details as provided by French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS):
Primary Outcome Measures:
- Natural history of HIV infection in Sub-Saharan Africa [ Time Frame: 12 months after ART initiation ]Plasmatic HIV viral load and CD4 measured every six months and incidence of morbidity events associated with AIDS
Secondary Outcome Measures:
- Estimate the probability of disease progression after HIV seroconversion [ Time Frame: 12 months after ART initiation ]Disease progression will be estimated with CD4 cell loss and time from seroconversion to clinical AIDS, death and antiretroviral therapy initiation
- Evolution of markers of HIV infection and immunity [ Time Frame: 12 months after ART initiation ]CD4 count, immune activation, plasma HIV-RNA intracellular, HIV-DNA
- Viral genetic diversity description [ Time Frame: Inclusion (J0) ]biomolecular analysis of HIV-1
- Primary resistance to antiretroviral treatment [ Time Frame: Inclusion (J0) ]Frequency of primary resistance to antiretroviral treatment (genotyping)
- Metabolic and lipodystrophic disorders [ Time Frame: 12 months after ART initiation ]Metabolic analysis (Total Cholesterol, HDL and LDL, Triglycerides) and lipodystrophia measurements
- Incidence of pregnancies [ Time Frame: 12 months after ART initiation ]Occurence of pregnancies
- T lymphocytes activation and evolution in seroconverters [ Time Frame: Inclusion ]Define parameters of activation of T lymphocytes and their evolution since primo-infection among individuals recently infected in West Africa; Expression of markers CD38, HLA-DR, CD28 and CD127 on CD4 and CD8 T cells by flux cytometry
- T lymphocytes activation and evolution in seroconverters [ Time Frame: 12 months after ART initiation ]Define parameters of activation of T lymphocytes and their evolution since primo-infection among individuals recently infected in West Africa; Expression of markers CD38, HLA-DR, CD28 and CD127 on CD4 and CD8 T cells by flux cytometry
Biospecimen Retention: Samples With DNA
Plasma and whole blood for PBMC preparation
| Estimated Enrollment: | 564 |
| Study Start Date: | June 1997 |
| Estimated Study Completion Date: | December 2014 |
| Estimated Primary Completion Date: | December 2014 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
HIV+ patients with an estimated date of seroconversion
It was estimated that 564 individuals, will be enrolled at the Blood Bank Medical Centre, including 364 individuals already followed-up (former PRIMOCI ANRS 1220 cohort started in 1997) and 200 newly enrolled individuals in this study.
|
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
All HIV infected individuals that will have had a contact with the Blood Bank Medical Center since 1992.
Criteria
Inclusion Criteria:
- patients included in the last Primo-CI ANRS 1220 protocol
- All HIV infected individuals diagnosed during a blood donation with an estimated date of HIV seroconversion that will respect the following criteria: (i) age ≥18 (ii) HIV-1 or HIV-1+2 infected, (iii) HIV-seronegative at the preceding donation; (iv) who returned to the clinic to be informed of their HIV test result (v) with an HIV serology confirmed with two specific tests in two different laboratories (vi) who have never received ART for curative purpose
- informed on study objectives and have a signed informed consent.
Exclusion Criteria:
- Patient living outside of Abidjan
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01917175
Please refer to this study by its ClinicalTrials.gov identifier: NCT01917175
Contacts
| Contact: Albert Minga, MD, PhD | +225 21 35 52 78 | minga.albert@yahoo.fr | |
| Contact: Patrick Coffie, MD, PhD | +225 21 75 59 60 | ahuatchi@gmail.com |
Locations
| Côte D'Ivoire | |
| Centre Médical du Suivi des Donneurs de Sang (Blood Bank Medical Centre) | Recruiting |
| Abidjan, Côte D'Ivoire | |
| Contact: Albert Kla Minga, MD, PhD +225 21 35 52 78 minga.albert@yahoo.fr | |
| Centre National de Transfusion Sanguine (National Blood Transfusion Centre) | Recruiting |
| Abidjan, Côte D'Ivoire | |
| Contact: Seidou Konaté, MD +22521355723 plasmaci@yahoo.fr | |
Sponsors and Collaborators
French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Investigators
| Principal Investigator: | Albert Kla Minga, MD, PhD | CMSDS, Abidjan, Côte d'Ivoire |
| Principal Investigator: | Patrick Coffie, MD, PhD | Programme PACCI, Abidjan, Côte d'Ivoire |
| Principal Investigator: | Charlotte Lewden, MD, PhD | Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED), Bordeaux, France |
More Information
Additional Information:
| Responsible Party: | French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) |
| ClinicalTrials.gov Identifier: | NCT01917175 History of Changes |
| Other Study ID Numbers: |
ANRS 1220/12277 PRECO-CI |
| Study First Received: | August 5, 2013 |
| Last Updated: | August 5, 2013 |
Keywords provided by French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS):
|
HIV Cohort Early HIV infection Côte d'Ivoire Disease progression |
Additional relevant MeSH terms:
|
Infection Communicable Diseases HIV Infections Acquired Immunodeficiency Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections |
Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases |
ClinicalTrials.gov processed this record on May 25, 2017